In fact, recently a biopharmaceutical company developing anti-MARCKS technology demonstrated the highly promising clinical efficacy without any serious adverse events of a novel peptidomimetic BIO-11006 that blocks MARCKS phosphorylation, from a phase 2 study in non-small cell lung cancer [172]. The gene discussed is MARCKS; the disease is non-small cell lung carcinoma.